Cardiol Therapeutics Inc. (CRDL)Healthcare | Drug Manufacturers - Specialty & Generic | Oakville, Canada | NasdaqCM
1.06 USD
+0.05
(4.950%)
⇧
(July 13, 2026, 4 p.m.
EDT)
After hours: 1.07 +0.01 (0.953%) ⇧ (July 13, 2026, 7:45 p.m. EDT) |
Hot Take ↕ | July 11, 2026, 4:24 a.m. EDT
The investment case for Cardiol Therapeutics is severely compromised by a deteriorating business reality masked by aggressive analyst optimism. Fundamentally, the company is bleeding cash with negative free cash flow and negative returns on both assets and equity. The balance sheet, while currently showing low debt relative to equity, is propped up by minimal cash reserves against a backdrop of continuous burn. The price action confirms this distress, with the stock down nearly 64% over the last six years and failing to recover despite a single strong year, leaving it in a multi-year downtrend. The disconnect between the 'strong buy' analyst consensus and the hard data is dangerous. Analysts are pricing in breakeven, but the operational metrics suggest the company is struggling to generate the revenue needed to sustain itself without further dilution or capital infusion. The options market reflects this fragility; the absence of put buyers suggests traders are ignoring the downside risk entirely, focusing only on the theoretical upside of a clinical success, which is a binary event with high failure probability. With no dividend to provide income and a long-term trajectory of structural decline, this is a speculative vehicle for high-risk tolerance investors only, not a sound investment. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.129911 |
| MSTL | 0.136061 |
| AutoARIMA | 0.145541 |
| AutoETS | 0.146723 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 32% |
| H-stat | 44.50 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.056 |
| Excess Kurtosis | -1.75 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 0.481 |
| Market Cap | 122,188,568 |
| Forward P/E | -5.36 |
| Beta | 0.51 |
| Website | https://www.cardiolrx.com |
As of July 11, 2026, 4:24 a.m. EDT: Options activity shows a distinct lack of protective put buying, with virtually zero open interest in the put market across all expirations. Conversely, there is significant call open interest concentrated at strikes far out-of-the-money ($5.00 and $7.50), suggesting speculative bets on a massive rally rather than hedging against downside risk. Implied volatility is extremely low, indicating complacency among traders regarding potential near-term moves.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.24060148 |
| Address1 | 2,265 Upper Middle Road East |
| Address2 | Suite 602 |
| All Time High | 10.0 |
| All Time Low | 0.45 |
| Ask | 1.3 |
| Ask Size | 2 |
| Audit Risk | 7 |
| Average Analyst Rating | 1.4 - Strong Buy |
| Average Daily Volume10 Day | 397,420 |
| Average Daily Volume3 Month | 474,042 |
| Average Volume | 474,042 |
| Average Volume10Days | 397,420 |
| Beta | 0.507 |
| Bid | 0.7632 |
| Bid Size | 2 |
| Board Risk | 2 |
| Book Value | 0.15238087 |
| City | Oakville |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 10 |
| Country | Canada |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 1.06 |
| Current Ratio | 4.387 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 1.09 |
| Day Low | 1.0 |
| Debt To Equity | 0.481 |
| Display Name | Cardiol Therapeutics |
| Earnings Timestamp End | 1,778,761,800 |
| Earnings Timestamp Start | 1,778,761,800 |
| Ebitda | -35,570,300 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -2.498 |
| Enterprise Value | 88,868,176 |
| Eps Current Year | -0.36 |
| Eps Forward | -0.1976744 |
| Eps Trailing Twelve Months | -0.27 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 1.17414 |
| Fifty Day Average Change | -0.11414003 |
| Fifty Day Average Change Percent | -0.09721161 |
| Fifty Two Week Change Percent | -24.060148 |
| Fifty Two Week High | 1.71 |
| Fifty Two Week High Change | -0.6500001 |
| Fifty Two Week High Change Percent | -0.380117 |
| Fifty Two Week Low | 0.88 |
| Fifty Two Week Low Change | 0.17999995 |
| Fifty Two Week Low Change Percent | 0.2045454 |
| Fifty Two Week Range | 0.88 - 1.71 |
| Financial Currency | CAD |
| First Trade Date Milliseconds | 1,547,562,600,000 |
| Float Shares | 96,504,767 |
| Forward Eps | -0.1976744 |
| Forward P E | -5.3623533 |
| Free Cashflow | -13,050,252 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 18 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.02382 |
| Held Percent Institutions | 0.24662 |
| Implied Shares Outstanding | 115,272,240 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Industry Disp | Drug Manufacturers - Specialty & Generic |
| Industry Key | drug-manufacturers-specialty-generic |
| Ipo Expected Date | 2,021-08-10 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38, a novel subcutaneously administered drug formulation of cannabidiol for the treatment of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada. |
| Long Name | Cardiol Therapeutics Inc. |
| Market | us_market |
| Market Cap | 122,188,568 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_424954803 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -36,349,808 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 116,920,493 |
| Number Of Analyst Opinions | 4 |
| Open | 1.01 |
| Operating Cashflow | -24,218,514 |
| Operating Margins | 0.0 |
| Overall Risk | 9 |
| Payout Ratio | 0.0 |
| Phone | 289 910 0850 |
| Post Market Change | 0.010100007 |
| Post Market Change Percent | 0.9528309 |
| Post Market Price | 1.0701 |
| Post Market Time | 1,783,986,333 |
| Previous Close | 1.01 |
| Price Eps Current Year | -2.9444442 |
| Price Hint | 4 |
| Price To Book | 6.9562535 |
| Profit Margins | 0.0 |
| Quick Ratio | 3.931 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.4 |
| Region | US |
| Regular Market Change | 0.05 |
| Regular Market Change Percent | 4.95049 |
| Regular Market Day High | 1.09 |
| Regular Market Day Low | 1.0 |
| Regular Market Day Range | 1.0 - 1.09 |
| Regular Market Open | 1.01 |
| Regular Market Previous Close | 1.01 |
| Regular Market Price | 1.06 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 1,268,233 |
| Return On Assets | -0.78247 |
| Return On Equity | -1.7396001 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 3 |
| Shares Outstanding | 115,272,240 |
| Shares Percent Shares Out | 0.019199999 |
| Shares Short | 2,217,703 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 1,918,255 |
| Short Name | Cardiol Therapeutics Inc. |
| Short Percent Of Float | 0.0198 |
| Short Ratio | 5.95 |
| Source Interval | 15 |
| State | ON |
| Symbol | CRDL |
| Target High Price | 8.740393 |
| Target Low Price | 4.8556952 |
| Target Mean Price | 7.2156014 |
| Target Median Price | 7.6331577 |
| Total Cash | 27,673,192 |
| Total Cash Per Share | 0.24 |
| Total Debt | 116,408 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.27 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.10906 |
| Two Hundred Day Average Change | -0.049060106 |
| Two Hundred Day Average Change Percent | -0.044235755 |
| Type Disp | Equity |
| Volume | 1,268,233 |
| Website | https://www.cardiolrx.com |
| Zip | L6H 0G5 |